-
Mashup Score: 74Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial - 2 month(s) ago
PURPOSE Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events. Therefore, we conducted this study to assess the efficacy of topical diclofenac in the prevention of capecitabine-induced HFS. METHODS In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned in a 1:1 ratio to receive topical diclofenac or placebo gel for 12 weeks or until the development of HFS, whichever occurred earlier. The primary end point was the incidence of grade 2 or 3 HFS (Common Terminology Criteria for Adverse Events version 5), which was compared between th
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
🔥 D-TORCH study demonstrates 1% topical diclofenac reduces capecitabine-associated hand-foot syndrome (15% v 3.8%) in #BreastCancer and #GastrointestinalCancers ➡️ https://t.co/T5xBWcR6rG @batraatulmd #supponc #BCSM #CRCSM https://t.co/2llQmZQa4d